Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | POLH | Q9Y253 | 6/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 6/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chrysin SCHEMBL44474 | 1.00 | MAPT (1.00) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL29383577 | 1.00 | MAPT (1.00) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL27736782 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL29183315 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL28150701 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL28107440 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL28879361 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL10809371 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL29183306 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A | |
| Chrysin SCHEMBL27657189 | 0.98 | MAPT (0.97) | MAPTCYP3A4ABCB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1342464-A | Antivirus antioxidizing active extract of proplis and its molecular inclusion compound | JIANG DEYONG (CN) | 2002-04-03 | — | — | CN | claimed |
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2011-03-10 | — | — | US | disclosed |
| US-7855200-B2 | Method for treatment of gastric ulcers and ulcers induced by aspirin | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2010-12-21 | — | — | US | disclosed |
| EP-1976508-A2 | FLAVONOIDS ISOLATED FROM OROXYLUM INDICUM FOR TREATMENT OF GASTROINTESTINAL TOXICITY, ASSOCIATED SYMPTOMS AND ULCERS | Council of Scientific and Industrial Research (IN) | 2008-10-08 | — | — | EP | disclosed |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-13 | — | — | US | disclosed |
| WO-2007080484-A2 | FLAVONOIDS ISOLATED FROM OROXYLUM INDICUM FOR TREATMENT OF GASTROINTESTINAL TOXICITY, ASSOCIATED SYMPTOMS AND ULCERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-07-19 | — | — | WO | disclosed |
| US-20050271755-A1 | Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2005-12-08 | — | — | US | disclosed |
| WO-2005112963-A2 | PHYTOMEDICINAL COMPOSITIONS FOR THE CONTROL OF LIPID ACCUMULATION AND METABOLISM IN MAMMALS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2005-12-01 | — | — | WO | disclosed |
| CN-1220497-C | Antivirus antioxidizing active extract of proplis and its molecular inclusion compound | JIANG DEYONG (CN) | 2005-09-28 | — | — | CN | disclosed |
| WO-2005009332-A2 | COMPOSITIONS-OF-MATTER FOR LOWERING SERUM CHOLESTEROL AND/OR TRIGLYCERIDE LEVEL AND METHODS OF PRODUCING AND USING SAME | PALSAMED (P.B.S.) LTD. (IL) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059913-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS | MLN, FABP6, SI | MAPT 4144/4885CYP3A4 178/4885ABCB1 981/4885 |
| US-20070213281-A1 | Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | FABP6, MLN, SI | MAPT 4278/4885CYP3A4 181/4885ABCB1 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.